Video

HER2CLIMB: Implications for Brain Metastases in HER2+ mBC

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, University Hospitals Seidman Cancer Center; associate professor, medicine, Case Western Reserve University School of Medicine
5 experts are featured in this series
Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer
Jian Zhang, MD
Related Content
Breast cancer | Image Credit: ©Sebastian Kaulitzki – stock.adobe.com
January 28th 2025

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 22nd 2025

SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
January 20th 2025

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12